Aardvark Therapeutics, Inc. (AARD) Stock Statistics & Valuation Metrics

Aardvark Therapeutics, Inc. has a market cap or net worth of $93.81M. The enterprise value is $47.20M.

Aardvark Therapeutics, Inc. has 21,816,042 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aardvark Therapeutics, Inc.’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -58.58%.

The current PE Ratio of Aardvark Therapeutics, Inc. is ―. Aardvark Therapeutics, Inc.’s PEG ratio is -0.05.

In the last 12 months, Aardvark Therapeutics, Inc. had revenue of 0.00 and earned -57.59M in profits. Earnings per share was -2.93.

In the last 12 months, operating cash flow was -54.17M and capital expenditures -95.00K, giving a free cash flow of -54.27M billion.

Aardvark Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Aardvark Therapeutics, Inc. upcoming earnings date is May 20, 2026, After Close (Confirmed).

Aardvark Therapeutics, Inc. as a current ratio of 10.61, with Debt / Equity ratio of 0.41%

In the past 12 months, Aardvark Therapeutics, Inc. has paid 0.00 in taxes.

Aardvark Therapeutics, Inc. EV to EBITDA ratio is -3.36, with an EV/FCF ratio of -3.89.

Aardvark Therapeutics, Inc. has $110.03M in cash and marketable securities with $441.00K in debt, giving a net cash position of $109.59M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Aardvark Therapeutics, Inc. is $13.26, which is 11.43% higher than the current price. The consensus rating is Moderate Buy